Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

ABBOTT LABORATORIES : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

10/21/2020 | 07:37am EST

Item 2.02 Results of Operations and Financial Condition

On October 21, 2020, Abbott Laboratories announced its results of operations for the third quarter 2020.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions and restructuring actions, charges related to cost reduction initiatives, the acquisition of R&D assets, charges related to impairment of certain assets, income related to certain litigation settlements, and tax benefits associated with specified items, tax benefits associated with the resolution of various tax positions related to prior years and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits





  Exhibit No. Exhibit




           99.1        Press Release dated October 21, 2020 (furnished pursuant
                     to Item 2.02).




         104         Cover Page Interactive Data File (the cover page XBRL tags
                     are embedded in the Inline XBRL document).

© Edgar Online, source Glimpses

All news about ABBOTT LABORATORIES
12/02ABBOTT LABORATORIES : FreeStyle Libre 2 Now Approved for Adults and Children wit..
AQ
11/20ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
11/19ABBOTT LABORATORIES : Becomes first anchor sponsor of american diabetes associat..
AQ
11/18ABBOTT LABORATORIES : Launches the first infant formula in canada with an ingred..
AQ
11/17ABBOTT LABORATORIES : Launches the First Infant Formula in Canada with an Ingred..
AQ
11/17ABBOTT LABORATORIES : Named industry sustainability leader for the eighth year i..
AQ
11/16HHS Official Says The Agency Has Responded To Every State That Has Requested ..
RE
11/16ABBOTT : Named Industry Sustainability Leader for the Eighth Year in a Row on th..
PR
11/12ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of..
AQ
11/12ABBVIE : Vice Chairman, Chief Commercial Officer Carlos Alban to Retire
DJ
More news
Financials (USD)
Sales 2020 33 873 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 44,0x
Yield 2020 1,34%
Capitalization 185 B 185 B -
EV / Sales 2020 5,81x
EV / Sales 2021 5,05x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 118,44 $
Last Close Price 107,90 $
Spread / Highest target 20,5%
Spread / Average Target 9,77%
Spread / Lowest Target -24,0%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES24.22%184 876
MEDTRONIC PLC0.35%150 831
BECTON, DICKINSON AND COMPANY-10.74%69 175
HOYA CORPORATION23.88%46 806
ALIGN TECHNOLOGY, INC.86.97%40 293
BAXTER INTERNATIONAL INC.-6.72%38 986